Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Zika virus seroprevalence in blood donors from the Northeastern region of Sao Paulo State, Brazil, between 2015 and 2017

Full text
Author(s):
Slavov, Svetoslav Nanev [1, 2] ; Guaragna Machado, Rafael Rahal [3] ; Ferreira, Alexander Rodrigo [2] ; Soares, Camila Pereira [3] ; Araujo, Danielle Bastos [3] ; Leal Oliveira, Danielle Bruna [3] ; Covas, Dimas Tadeu [2] ; Durigon, Edison Luiz [3] ; Kashima, Simone [2]
Total Authors: 9
Affiliation:
[1] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Internal Med, BR-14049900 Ribeirao Preto, SP - Brazil
[2] Univ Sao Paulo, Fac Med Ribeirao Preto, Blood Ctr Ribeirao Preto, Lab Mol Biol, 2501 Tenente Catao Roxo St, BR-14051140 Ribeirao Preto, SP - Brazil
[3] Univ Sao Paulo, Inst Biomed Sci, Lab Clin & Mol Virol, BR-05508000 Sao Paulo, SP - Brazil
Total Affiliations: 3
Document type: Journal article
Source: Journal of Infection; v. 80, n. 1, p. 111-115, JAN 2020.
Web of Science Citations: 0
Abstract

Objectives: Although primarily transmitted by Aedes aegypti mosquitos, Zika virus (ZIKV) can also be transmitted by blood transfusion, due to the fact that some of the infected donors can establish asymptomatic viremia. ZIKV seroprevalence in Brazilian blood donors is unknown. The main reason for this gap in the knowledge originates from the difficulty in evaluating ZIKV humoral immunity due to antigenic cross-reactivity between the different Brazilian flaviviruses and, in particular, dengue virus (DENV). The objective of this study was to evaluate the anti-ZIKV IgG prevalence in blood donors from the Northeast region of the Sao Paulo State, Brazil, which experienced a ZIKV outbreak in 2016. Methods: We evaluated the ZIKV seroprevalence using the NS1 anti-ZIKV IgG test (Euroimmun), followed by confirmation of the positive and borderline results using the Plaque Reduction Neutralization Test (PRNT). ZIKV seroprevalence was estimated by testing plasma samples collected in 2015 (before the ZIKV outbreak), 2016 (during the outbreak) and 2017 (after the outbreak). In order to investigate possible antigenic cross - reactivity between ZIKV and DENV we also included samples that were taken well before the ZIKV outbreak, in years 2010 and 2013. Results: The results obtained by the Euroimmun anti-ZIKV IgG test demonstrated ZIKV seroreactivity in 2015, 2016, and 2017 with prevalences of 5.3%, 12.8% and 13.2%, respectively. The inclusion of blood donor samples from 2010 to 2013, demonstrated anti-ZIKV IgG reactivity only for 2013 (1.7%). The PRNT testing of the ZIKV positive and borderline ELISA reacting samples generated positive results only for the years of 2016 and 2017 (prevalences of 5.6% and 9.1%) which coincided with the introduction of ZIKV in our region. Conclusions: Our results estimate for the first time the ZIKV seroprevalence among Brazilian blood donors from a region with apparently extensive ZIKV circulation and which, at the same time, is highly endemic for DENV. We detected relatively low ZIKV seroprevalence in blood donors from the studied region probably due to the lower intensity of the outbreak compared to other Brazilian locations. Our study adds to the global understanding of ZIKV circulation and the herd immunity of the exposed population. (C) 2019 The British Infection Association. Published by Elsevier Ltd. All rights reserved. (AU)

FAPESP's process: 17/23205-8 - Evaluation of the impact of emerging and reemerging viruses in the field of hemotherapy and stem cell transplantation by multiple-research approach
Grantee:Svetoslav Nanev Slavov
Support Opportunities: Research Grants - Young Investigators Grants
FAPESP's process: 16/20045-7 - Antigen discovery and development of serological diagnostic methods and vaccine approaches against the Zika Virus (ZIKV)
Grantee:Luis Carlos de Souza Ferreira
Support Opportunities: Research Projects - Thematic Grants
FAPESP's process: 16/15049-3 - Development and validation of multiplex molecular platform for confirmatry diagnosis of Zika virus infection and establishment of laboratory standards
Grantee:Simone Kashima Haddad
Support Opportunities: Research Grants - Research in Public Policies for the National Health Care System (PP-SUS)
FAPESP's process: 16/08727-5 - Development of serological assay for Zika virus IgG and IgM based on low coast ELISA
Grantee:Danielle Bruna Leal de Oliveira
Support Opportunities: Research Grants - Innovative Research in Small Business - PIPE
FAPESP's process: 14/50947-7 - INCT 2014: in Stem Cell and Cell Therapy
Grantee:Dimas Tadeu Covas
Support Opportunities: Research Projects - Thematic Grants